BPGBIO HIGHLIGHTS PRELIMINARY CLINICAL FINDINGS FROM ONGOING PHASE 2 GBM STUDY

BPM31510 GBM ONGOING TRIAL DATA

Phase 2 findings presented at ASCO 2026 showed strong median overall survival of 19.3 months in evaluable patients, led by 29.3 months in MGMT unmethylated GBM patients

Format

PNG

Source

BPGbio

Téléchargements